Researchers have identified over 150 cannabinoids in the cannabis plant, but they’ve studied only a handful in real depth. At least 104 distinct phytocannabinoids exist in Cannabis sativa alone. Every one of them interacts with a regulatory system in your body that governs pain, inflammation, mood, appetite, and immune function. Scientists didn’t discover that system, the endocannabinoid system, until the 1990s — making it one of the most recently identified major biological systems in human physiology.
This guide breaks down what cannabinoids actually are, how the endocannabinoid system works, and how the major compounds — THC, CBD, CBG, CBN, and a handful of minor players — differ from each other at a mechanistic level.
What Are Cannabinoids at the Molecular Level?
Chemically, cannabinoids are C21 terpenophenolic compounds built on a 31-carbon backbone. Mechoulam and Gaoni first isolated and mapped the structure of THC back in 1965, a discovery that essentially launched the modern science of cannabinoids. Every major cannabinoid traces back to a single precursor molecule, cannabigerolic acid (CBGA). Specific synthase enzymes convert CBGA into THCA, CBDA, and CBCA. Heat then converts those acidic forms into the neutral compounds most people associate with cannabis — the process known as decarboxylation.
Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids
Cannabinoids fall into three distinct categories, and the differences matter. Plants produce over 150 identified “phytocannabinoids” in cannabis, and researchers have found related compounds in other plants entirely, including Echinacea and liverwort. Most act as partial agonists at cannabinoid receptors. Your own body produces “endocannabinoids”: anandamide, named from the Sanskrit word for “bliss,” was the first one identified, followed a few years later by 2-arachidonoylglycerol (2-AG). Unlike plant cannabinoids, these are full agonists that your body synthesizes on demand rather than stores. Labs create “synthetic cannabinoids” — dronabinol and CBD-based Epidiolex are FDA-approved examples, and some experimental synthetics bind CB1 receptors up to 100 times more strongly than THC itself.
Acidic vs. Neutral Cannabinoid Forms
Raw cannabis contains mostly acidic cannabinoids before any heat touches it — THCA and CBDA rather than THC and CBD. These acidic forms aren’t intoxicating, but they’re not inert either: researchers have found THCA carries anti-inflammatory properties distinct from THC, and CBDA binds roughly 100 times more strongly to 5-HT1A receptors than CBD does. Decarboxylation, which happens around 220–240°F, converts one form into the other
What Is the Endocannabinoid System?
Scientists pieced this system together surprisingly recently. Researchers characterized the CB1 receptor in rat brain tissue in 1988, discovered the CB2 receptor in immune cells five years later, and only proposed the endocannabinoid system as a unified regulatory mechanism in 1995. That’s a 30-year-old field of science studying a system that’s been running in your body your entire life.
Cannabinoid Receptors
The system has three core components, starting with two receptor types. CB1 receptors rank as the most abundant G-protein coupled receptors in the mammalian brain, concentrated in the hippocampus, basal ganglia, and cerebellum, at roughly ten times the density of opioid receptors. CB2 receptors sit primarily in immune cells and peripheral tissue, though researchers have also found them in brain microglia, overturning the earlier assumption that they were absent from the central nervous system.
Endocannabinoids and Metabolic Enzymes
Endocannabinoids are the body’s own signaling molecules — 2-AG is roughly 170 times more abundant in brain tissue than anandamide, and both act as retrograde neurotransmitters, traveling backward across synapses in a way most neurotransmitters don’t. Metabolic enzymes, primarily FAAH and MAGL, break down anandamide and 2-AG respectively once they’ve done their job.
Where Cannabinoid Receptors Live in the Body
This receptor network reaches nearly everywhere: the basal ganglia for motor control, the hippocampus for memory, the cerebellum for coordination, the prefrontal cortex for decision-making, plus the spleen, gut, liver, and skin. That wide distribution largely explains why cannabinoids produce such varied effects depending on dose, ratio, and individual physiology.
How Do the Major Cannabinoids Work in Your Body?
THC (Δ9-Tetrahydrocannabinol)
THC is a partial CB1 agonist, working at roughly 25% efficacy compared to a full agonist. It inhibits adenylyl cyclase through Gi/o proteins, and its psychoactive effects come from CB1 activation in the brain’s reward pathways and prefrontal cortex. THC’s dose-response curve is famously biphasic — research has found low doses tend to be anxiolytic while higher doses become anxiogenic, with a therapeutic window generally cited at 2.5–20mg orally. Onset is fast when inhaled, typically 3–10 minutes, but stretches to 1–5 hours with oral consumption.
CBD (Cannabidiol)
CBD works almost entirely differently. It shows minimal direct binding to CB1 or CB2 receptors, and instead functions as a negative allosteric modulator of CB1 — meaning it changes how the receptor responds to other compounds rather than activating it directly. CBD also hits several other targets: a 5-HT1A serotonin receptor (its anxiolytic mechanism), GPR55 (anti-inflammatory), TRPV1 (pain and inflammation), and PPARγ (neuroprotection). It’s also the active mechanism behind the entourage effect’s best-documented example — CBD reduces THC-induced anxiety and paranoia when the two are used together. Clinical doses run from 300–600mg for anxiety up to 20mg/kg for Epidiolex’s epilepsy indication.
CBG (Cannabigerol)
People often call CBG the “mother cannabinoid” since every other cannabinoid derives from its precursor, yet it typically makes up less than 1% of most strains despite that central biosynthetic role. It acts as an α2-adrenoceptor agonist, shown to reduce intraocular pressure, and demonstrates anti-inflammatory effects in inflammatory bowel disease models. Lab research has also shown it fights MRSA — a genuinely unexpected direction for a cannabinoid.
CBN (Cannabinol)
CBN forms as THC oxidizes and degrades over time, which is why older cannabis tends to carry more of it. A 2024 study offered the first objective evidence that CBN’s effect on sleep matches zolpidem, a common prescription sleep aid, while carrying only about 10% of THC’s psychoactive potency. That combination — real sedative potential with minimal intoxication — has made CBN the fastest-growing minor cannabinoid in sleep products specifically.
Other Minor Cannabinoids Worth Knowing
A few other minor cannabinoids are worth knowing. THCV acts as a CB1 antagonist at low doses and an agonist at high doses, and unlike THC, it’s associated with appetite suppression rather than stimulation, with early research pointing toward glycemic control benefits in type 2 diabetes. CBC produces significant anti-inflammatory and analgesic effects and appears to promote neurogenesis in neural stem cells, all without psychoactivity. CBDV has demonstrated anticonvulsant activity in animal models and is currently in clinical trials for autism spectrum disorder.
What Is the Entourage Effect?
Researchers first proposed the idea that cannabinoids and terpenes work better together than in isolation in 1999. Ethan Russo’s 2011 review, “Taming THC,” remains the most comprehensive treatment of the concept. The proposed mechanisms include enhanced receptor binding, improved cannabinoid absorption, altered enzymatic breakdown, and genuinely multi-target activity across the many compounds cannabis produces at once.
The supporting evidence is real, if not fully settled. One study found a CBD-rich extract outperformed pure, isolated CBD for inflammation, producing a bell-shaped dose-response curve that isolate alone didn’t show. Another found a full-spectrum extract needed a dose four times lower than an isolate to match its pain relief in animal models. A third found cannabis extract outperformed isolated cannabinoids against cancer cells in vitro.
That said, the entourage effect isn’t universally accepted. Some researchers argue the high-quality human evidence remains limited, and others suggest precisely defined cannabinoid combinations might eventually outperform whole-plant extracts once researchers identify the right ratios. Epidiolex itself proves isolated cannabinoids can work well on their own for the right condition — the entourage effect isn’t a requirement for efficacy, just one possible advantage among several approaches.
What’s Next for Cannabinoid Research?
The field is still young, and the gaps are real: a lack of standardized products across trials, historically restricted research access under Schedule I, and a genuine shortage of long-term safety data beyond five years. The National Academies identified three top priorities: head-to-head comparisons with standard treatments, optimal dosing, and predictive biomarkers.
Emerging Applications to Watch
A few emerging directions stand out. Preclinical cancer research continues to show anti-tumor effects and reduced metastasis in animal models, though human trials remain early-stage. In addiction treatment, CBD has reduced heroin cue-induced cravings in trials — a genuinely counterintuitive finding given cannabis’s own dependence potential. And in autism spectrum disorder, CBD-rich cannabis has shown measurable improvements in behavioral symptoms and quality-of-life measures, with Phase II/III trials now underway.
Longer term, expect more FDA-approved cannabinoid medications beyond Epidiolex, deeper research into the minor cannabinoids covered above, and genuinely personalized approaches — genomic profiling matched to specific cannabinoid ratios, rather than one-size-fits-all dosing.
Shop Cannabinoids the Easy Way
Skip the guesswork. Our cannasseurs can walk you through cannabinoid ratios and formulations in person, and help you find what actually matches what you’re looking for.
Shop All
